Health Care·Pharmaceuticals·$3.2B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-23.10 | N/A | -1371.34% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-23.10 | N/A | -1371.34% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concern over the current financial performance and highlighted the necessity for changes to improve results. They did not provide specific guidance for future quarters.
Management acknowledged the significant EPS loss and indicated ongoing challenges.
They emphasized the need for strategic adjustments moving forward.
Alumis Inc's earnings report shows a significant EPS loss, which is concerning for investors. Despite this, the stock rose by 4.59%, likely due to market reactions to other factors or investor sentiment. The lack of revenue data and guidance may lead to uncertainty in future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
ERASCA INC
Aug 12, 2024